EUVIMEDEUVIMED entdecken
Crossref

Glucagon Resistance in Individuals With Obesity and Hepatic Steatosis Can Be Measured Using the GLUSENTIC Test and Index

Sasha A S Kjeldsen, Michael M Richter, Nicole J Jensen iD, Malin S D Nilsson, Niklas Heinz, Janus D Nybing, Frederik H Linden, Erik Høgh-Schmidt, Mikael P Boesen, Thomas L Andersen, Helle H Johannesen, Samuel A J Trammell und 13 weitere

Diabetes · 2024

DOI: 10.2337/db23-0858 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, 2024. Verfasst von Sasha A S Kjeldsen und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Biochemistry, Copenhagen University Hospital Bispebjerg and Frederiksberg, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Glucagon, Fatty Liver, Obesity. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Novo Nordisk Fonden, Danmarks Frie Forskningsfond, Aase og Ejnar Danielsens Fond.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Increased plasma levels of glucagon (hyperglucagonemia) promote diabetes development but are also observed in patients with metabolic dysfunction–associated steatotic liver disease (MASLD). This may reflect hepatic glucagon resistance toward amino acid catabolism. A clinical test for measuring glucagon resistance has not been validated. We evaluated our glucagon sensitivity (GLUSENTIC) test, which consists of 2 study days: a glucagon injection and measurements of plasma amino acids and an infusion of mixed amino acids and subsequent calculation of the GLUSENTIC index (primary outcome measure) from measurements of glucagon and amino acids. To distinguish glucagon-dependent from insulin-dependent actions on amino acid metabolism, we also studied patients with type 1 diabetes (T1D). The δ-decline in total amino acids was 49% lower in MASLD following exogenous glucagon (P = 0.01), and the calculated GLUSENTIC index was 34% lower in MASLD (P < 0.0001) but not T1D (P > 0.99). In contrast, glucagon-induced glucose increments were similar in control participants and participants with MASLD (P = 0.41). The GLUSENTIC test and index may be used to measure glucagon resistance in individuals with obesity and MASLD. Article Highlights

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucagonFatty LiverObesityHumansMaleFemaleMiddle AgedAdultDiabetes Mellitus, Type 1Amino AcidsBlood Glucose

Substanzen

GlucagonAmino AcidsBlood Glucose

Autor:innen und Institutionen

  • Department of Clinical Biochemistry, Copenhagen University Hospital Bispebjerg and Frederiksberg, Copenhagen, Denmark.
  • Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Department of Endocrinology, Copenhagen University Hospital Bispebjerg and Frederiksberg, Copenhagen, Denmark.
  • Department of Radiology, Copenhagen University Hospital Bispebjerg and Frederiksberg, Copenhagen, Denmark.
  • Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.

ORCID-Profile: Nicole J Jensen, Sten Madsbad, Kirsten Nørgaard, Signe Schmidt, Jens J Holst, Nicolai J Wewer Albrechtsen

Förderung

  • Novo Nordisk Fonden
  • Danmarks Frie Forskningsfond
  • Aase og Ejnar Danielsens Fond
  • European Foundation for the Study of Diabetes
  • Fonden til Lægevidenskabens Fremme

Zitieren

APA

Kjeldsen, S. A. S., Richter, M. M., Jensen, N. J., Nilsson, M. S. D., Heinz, N., Nybing, J. D., Linden, F. H., Høgh-Schmidt, E., Boesen, M. P., Andersen, T. L., Johannesen, H. H., Trammell, S. A. J., Grevengoed, T. J., Madsbad, S., Vilstrup, H., Schiødt, F. V., Møller, A., Rashu, E. B., Nørgaard, K., …, & Wewer Albrechtsen, N. J. (2024). Glucagon Resistance in Individuals With Obesity and Hepatic Steatosis Can Be Measured Using the GLUSENTIC Test and Index. Diabetes. https://doi.org/10.2337/db23-0858

Vancouver

Kjeldsen SAS, Richter MM, Jensen NJ, Nilsson MSD, Heinz N, Nybing JD, et al. Glucagon Resistance in Individuals With Obesity and Hepatic Steatosis Can Be Measured Using the GLUSENTIC Test and Index. Diabetes. 2024. doi:10.2337/db23-0858

BibTeX
@article{Kjeldsen2024,
  author = {Kjeldsen, Sasha A S and Richter, Michael M and Jensen, Nicole J and Nilsson, Malin S D and Heinz, Niklas and Nybing, Janus D and Linden, Frederik H and Høgh-Schmidt, Erik and Boesen, Mikael P and Andersen, Thomas L and Johannesen, Helle H and Trammell, Samuel A J and Grevengoed, Trisha J and Madsbad, Sten and Vilstrup, Hendrik and Schiødt, Frank Vinholt and Møller, Andreas and Rashu, Elias B and Nørgaard, Kirsten and Schmidt, Signe and Gluud, Lise L and Haugaard, Steen B and Holst, Jens J and Rungby, Jørgen and Wewer Albrechtsen, Nicolai J},
  title = {Glucagon Resistance in Individuals With Obesity and Hepatic Steatosis Can Be Measured Using the GLUSENTIC Test and Index},
  journal = {Diabetes},
  year = {2024},
  doi = {10.2337/db23-0858}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche